BioInvent(Sweden, STO: BINV)
Bioinvent had several research programs on going but was unable to attract significant capital or interest from potential strategic partners. Bioinvent therefore hired Extera to re-position the product story and to enter into strategic collaborations.
Extera led de novo indication selection process with KOLs that led to a Phase I/II autologous stem cell transplant study in MM. Extera also repositioned other R&D programs, identify potential industry partners and created significant interest leading to major immune-oncology research collaboration between BioInvent and Pfizer. This collaboration enabled significant public fund raising
$300m research collaboration followed by major public financing